Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

In recent years, the broadening understanding of the pathogenesis of atopic dermatitis (AD)
has led to the development of novel therapeutic molecules, that target core inflammatory …

Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by
2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood …

Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for
the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab …

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-
severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical …

Introduction Numerous cutaneous dermatoses mediated by cytokines depend on the JAK
STAT pathway for intracellular signaling. JAK inhibitors form a useful therapeutic approach …

Atopic dermatitis (AD) is a common chronic inflammatory skin disease recognized as a
global health problem. 1, 2 The Global Burden of Disease Study revealed that dermatitis …

Introduction Lebrikizumab and dupilumab are monoclonal antibodies approved for treating
moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over …

Atopic dermatitis is an inflammatory skin disease, the prevalence of which has increased in
the last decade. It affects all age groups, with adult involvement being a major focus of …

Atopic dermatitis (AD) is a chronic inflammatory disease requiring efficacious and safe long-
term therapy. Several new systemic treatments have recently been approved for use in …